|
Roche reports positive study of RoACTEMRA given by subcutaneous injection
|
07 May 2012 |
|
Roche on track for full-year targets - good sales growth in first quarter
|
13 April 2012 |
|
Roche sends second letter to Illumina shareholders
|
04 April 2012 |
|
Roche disappointed by Illumina, Inc.'s Board of Directors' rejection
|
03 April 2012 |
|
Roche's Herceptin given by subcutaneous injection offers greater convenience and reduces costs
|
26 March 2012 |
|
Roche receives request for additional information from the Federal Trade Commission
|
14 March 2012 |
|
Roche Annual General Meeting 2012
|
06 March 2012 |
|
Positive One Year results From Phase 3 Study in Central Retinal Vein Occlusion of VEGF Trap-Eye
|
20 February 2012 |
|
FDA grants Roche's pertuzumab Priority Review for previously untreated HER2-positive metastatic breast cancer
|
13 February 2012 |
|
Roche in 2011: Strong results and positive outlook
|
07 February 2012 |
|
Roche supports cancer care development program in Ethiopia
|
23 January 2012 |
|
FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer
|
21 November 2011 |
|
Roche reports positive study of Herceptin given by subcutaneous injection
|
19 October 2011 |
|
Roche achieves significant progress with personalised healthcare
|
14 October 2011 |
|
Roche's investigational medicine T-DM1 shows improvement in progression-free survival
|
26 September 2011 |
|
Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year
|
12 September 2011 |
|
Roche’s Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer
|
06 September 2011 |
|
FDA approves Zelboraf and companion diagnostic for BRAF mutation-positive metastatic melanoma
|
18 August 2011 |
|
Roche's investigational treatment for asthma met its primary endpoint
|
08 August 2011 |
|
"Roche Continents" at the Salzburg Festival celebrates its five-year anniversary
|
28 July 2011 |